Assessment of patients' immune cells and efficacy of CAR-T cell therapy.

Treatment efficacy and safety of CAR-T cell therapy evaluated by the assessment of patients' immune cells. - Treatment efficacy and safety of CAR-T cell therapy evaluated by the assessment of patients' immune cells.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000058492

Enrollment

Registered

2025-07-16

Start date

2025-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

To adjust the dose and duration of therapeutic drugs for adverse events based on patients&#39

immune cells after CAR-T cell therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hematological malignancies treated with CAR-T cell therapy.

Exclusion criteria

Exclusion criteria: Patients with hematological malignancies who are not treated with CAR-T cell therapy.

Design outcomes

Primary

Measure	Time frame
Overall survivals for 3 years after CAR-T cell therapy.	—

Countries

Japan

Contacts

Public ContactToshiki Ochi

Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases

ochi.toshiki.eg@ehime-u.ac.jp089-960-5296

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Assessment of patients&#39; immune cells and efficacy of CAR-T cell therapy.